KCT0004592
Recruiting
未知
A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the evaluation of the efficacy and safety of 7-MEGATM500 on the Skin wrinkle improvement
Vitech0 sites90 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the skin and subcutaneous tissue
- Sponsor
- Vitech
- Enrollment
- 90
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Adult men and women subjects aged 30 older or under 60
- •2\) The subjects with eye crease grade 3 or higher in visual evaluation
- •3\) The subjects who have agreed to participate in this test prior to the start of the test and have signed a written consent form
Exclusion Criteria
- •1\) The subjects who have or are currently undergoing treatment for skin diseases such as atopic dermatitis and psoriasis
- •2\) The subjects who are sensitive or allergic to food for testing
- •3\) The subjects with abnormal skin conditions such as spots, acne, erythema, and capillary dilation in the test area
- •4\) Based on Visit 1, a person who received treatment on the facial (skin stripping, other skin care, etc.) or received treatment on the facial area within 6 months
- •5\) Based on Visit 1, a person who used a skin external substance containing steroids on the facial part or take an oral retinoid/steroid agent within 3 months of the standard visit
- •6\) Based on Visit 1, a person who used functional cosmetic (retinoid agent, retinol, AHA) or moisturizing cosmetic or skin care (LED mask, ion booster, etc.) to improve wrinkles within 2 weeks of visit
- •7\) Based on Visit 1, a person who has taken diet pills (absorbent and antidepressants, appetite suppressants, etc.) and contraceptives or hormones or diuretics within one month
- •8\) Based on Visit 1, a person who has taken health function foods containing antioxidants, hyaluronic acids, collagen, freedom of the moon flower, Omega 3, 6 fatty acids such as violet oil, krill oil, persimmon\-nolene acid, affluence of manic tree oil (Omega\-7\), vitamin A, vitamin C, vitamin E, DHA/EPA, and other medicinal products consumed within two weeks
- •9\) Based on Visit 1, a person who has participated in other interventional clinical tests (including human application tests) within one month of the standard or plans to participate in other interventional clinical tests (including human application tests) after the start of this human application test.
- •10\) AST (GOT) or ALT (GPT) or ?\-GTP is three times the normal scope of the testing agency
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A Clinical Trial for the evaluation of the efficacy and safety of RW0117 on dyspepsiaKCT0005265Richwood Trading Company, LTD.100
Not yet recruiting
Not Applicable
The efficacy and safety of CT20S on the Skin wrinkle improvementKCT0004447P&K Skin Research Center120
Recruiting
Not Applicable
The Efficacy and Safety of KD501 on Memory ImprovementKCT0004424Wonkwang University. Iksan Korean Medicine Hospital80
Active, not recruiting
Phase 1
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisEUCTR2017-002177-20-ATAllergan Ltd.311
Active, not recruiting
Phase 1
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2017-002177-20-ROAllergan Ltd.311